GRAIL/$GRAL
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About GRAIL
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
- Ticker
- $GRAL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 910
- Headquarters
- Sunnyvale, United States
- Website
- grail.com
GRAIL Metrics
BasicAdvanced
$5.2B
-
-$9.27
2.87
-
Price and volume
Market cap
$5.2B
Beta
2.87
52-week high
$166.48
52-week low
$41.50
Average daily volume
951K
Financial strength
Current ratio
8.934
Quick ratio
8.562
Long term debt to equity
0.032
Total debt to equity
0.035
Profitability
EBITDA (TTM)
-398.217
Gross margin (TTM)
46.68%
Net profit margin (TTM)
-243.80%
Operating margin (TTM)
-332.04%
Effective tax rate (TTM)
25.89%
Revenue per employee (TTM)
$180,000
Management effectiveness
Return on assets (TTM)
-12.97%
Return on equity (TTM)
-17.31%
Valuation
Price to revenue (TTM)
30.493
Price to book
2.11
Price to tangible book (TTM)
7.34
Price to free cash flow (TTM)
-16.283
Free cash flow yield (TTM)
-6.14%
Free cash flow per share (TTM)
-7.117
Growth
Revenue change (TTM)
17.47%
Earnings per share change (TTM)
-20.24%
What the Analysts think about GRAIL
Analyst ratings (Buy, Hold, Sell) for GRAIL stock.
Analyst projections of the future price of GRAIL stock.
Bulls say / Bears say
In the NHS-Galleri trial, later screening rounds showed fewer stage IV diagnoses, and emergency cancer presentations were lower in the test group. These encouraging signals suggest Galleri may help shift some diagnoses to an earlier point, although the trial’s main endpoint was not met. (PubMed Central)
The FDA advisory panel voted in favour of Galleri, bringing a potential approval decision closer. Approval could open a path to Medicare coverage from 2028, which would materially broaden access if coverage is secured. (Reuters)
Galleri test volumes grew 24% year over year in the third quarter and 36% over the first nine months of 2026. That growth suggests demand is building even before FDA approval or broad insurance coverage. (GRAIL)
The large NHS-Galleri trial did not meet its main goal: the combined rate of stage III and IV cancers was not significantly lower with screening. Whether Galleri reduces cancer deaths remains unproven. (PubMed Central)
Galleri detected only about 31% of all cancers diagnosed within a year of a test in the NHS trial, so a negative result can miss many cancers. Around half of positive results led to a cancer diagnosis, leaving others to face follow-up tests without a cancer finding. (BJC Reports)
Commercial growth is not yet translating into stronger financial performance: third-quarter revenue rose just 4%, while the adjusted EBITDA loss widened to $92.6 million. This leaves GRAIL dependent on continued funding while it builds its market. (GRAIL)
Data summarised monthly by Lightyear AI. Last updated on 14 Nov 2026.
GRAIL Financial Performance
Revenues and expenses
GRAIL Earnings Performance
Company profitability
Upcoming events
No upcoming events
GRAIL News
AllArticlesVideos
Funds containing GRAIL
Fund name | Fund size | $GRAL weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.6B | 0.47% |
iShares Healthcare Innovation€2B78 | $1.6B | 0.47% |
iShares Healthcare Innovation$HEAL | $1.6B | 0.47% |
iShares Nasdaq US Biotechnology$BTEC | $1.3B | 0.35% |
iShares Nasdaq US Biotechnology£BTEK | $1.3B | 0.33% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.


